Supernus Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US8684591089

Introduction

This page provides a comprehensive analysis of the known insider trading history of Victor Vaughn. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Victor Vaughn has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:SUPN / Supernus Pharmaceuticals, Inc. Sr. VP of Sales & Marketing 38,400
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Victor Vaughn. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases SUPN / Supernus Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in SUPN / Supernus Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SUPN / Supernus Pharmaceuticals, Inc. Insider Trades
Insider Sales SUPN / Supernus Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in SUPN / Supernus Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SUPN / Supernus Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Victor Vaughn as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2018-04-20 2018-04-19 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise X -7,850 38,400 -16.97
2018-04-20 2018-04-19 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
S - Sale X -7,850 9,344 -45.66 49.03 -384,855 458,100
2018-04-20 2018-04-19 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
M - Exercise X 7,850 17,194 84.01 25.30 198,605 435,008
2018-04-20 2018-04-18 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise X -3,750 46,250 -7.50
2018-04-20 2018-04-18 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise X -6,250 25,000 -20.00
2018-04-20 2018-04-18 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
S - Sale X -10,000 9,344 -51.70 47.06 -470,617 439,745
2018-04-20 2018-04-18 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
M - Exercise X 3,750 19,344 24.05 25.30 94,875 489,403
2018-04-20 2018-04-18 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
M - Exercise X 6,250 15,594 66.89 12.98 81,125 202,410
2018-04-09 2018-04-05 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise X -18,750 31,250 -37.50
2018-04-09 2018-04-05 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise X -26,250 8,750 -75.00
2018-04-09 2018-04-05 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise X -15,000 0 -100.00
2018-04-09 2018-04-05 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
S - Sale X -18,750 9,344 -66.74 45.33 -849,928 423,559
2018-04-09 2018-04-05 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
M - Exercise X 18,750 28,094 200.66 12.98 243,375 364,660
2018-04-09 2018-04-05 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
S - Sale X -26,250 9,344 -73.75 45.33 -1,189,899 423,559
2018-04-09 2018-04-05 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
M - Exercise X 26,250 35,594 280.93 9.13 239,662 324,973
2018-04-09 2018-04-05 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
S - Sale X -15,000 9,344 -61.62 45.33 -679,942 423,559
2018-04-09 2018-04-05 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
M - Exercise X 15,000 24,344 160.53 9.24 138,600 224,939
2018-02-16 2018-02-14 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
A - Award 33,000 33,000
2018-01-17 2018-01-17 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise X -15,000 15,000 -50.00
2018-01-17 2018-01-17 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise X -9,250 0 -100.00
2018-01-17 2018-01-17 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
S - Sale X -15,000 9,344 -61.62 47.03 -705,500 439,479
2018-01-17 2018-01-17 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
M - Exercise X 15,000 24,344 160.53 9.24 138,600 224,939
2018-01-17 2018-01-17 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
S - Sale X -9,250 9,344 -49.75 45.00 -416,250 420,480
2018-01-17 2018-01-17 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
M - Exercise X 9,250 18,594 98.99 7.90 73,075 146,893
2018-01-16 2018-01-12 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise X -5,750 9,250 -38.33
2018-01-16 2018-01-12 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
S - Sale X -5,750 9,344 -38.09 45.03 -258,928 420,769
2018-01-16 2018-01-12 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
M - Exercise X 5,750 15,094 61.54 7.90 45,425 119,243
2018-01-09 2018-01-09 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise X -15,000 15,000 -50.00
2018-01-09 2018-01-09 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
S - Sale X -15,000 9,344 -61.62 42.04 -630,650 392,853
2018-01-09 2018-01-09 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
M - Exercise X 15,000 24,344 160.53 7.90 118,500 192,318
2018-01-04 2018-01-02 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise X -55,000 30,000 -64.71
2018-01-04 2018-01-02 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
S - Sale X -55,000 9,344 -85.48 40.11 -2,206,308 374,832
2018-01-04 2018-01-02 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
M - Exercise X 55,000 64,344 588.61 7.90 434,500 508,318
2017-02-27 2017-02-24 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
A - Award 50,000 50,000
2016-03-03 2016-03-01 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
A - Award 50,000 50,000
2015-03-05 2015-03-03 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
A - Award 35,000 35,000
2014-01-23 2014-01-21 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
A - Award 30,000 30,000
2013-02-07 2013-02-05 4 SUPN SUPERNUS PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
A - Award 85,000 85,000
2013-02-07 3/A SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
4,082
2013-01-24 3 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock
700
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)